

Remarks

I. Preliminary Amendment

Applicants have amended the first page of the specification by amending the sentence to reflect current priority claims.

Applicants have cancelled claims 1-14 and 16-21 without prejudice to Applicants' right to file divisional applications directed to the subject matter not contained therein.

Applicants have amended claim 15 to reflect cancellation of claims 1-12, and to change the claim from a compound to a medicament.

The Applicants do not believe that any additional fees are due; however, the Office has the authority to charge the Applicants' Deposit Account for any fees that are presently due, or any fees that will become due. Please charge any appropriate fees to Deposit Account No. 19-1025.

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, he or she is cordially invited to contact Applicant's representative at the below listed number.

Respectfully submitted,



Rachel A. Polster

Agent for Applicants

Reg. No. 47,004

314-274-7354 (St. Louis)

Pfizer Inc
Corporate Patent Law Department
P.O. Box 1027
Chesterfield, Missouri 63006